Adial Pharmaceuticals Inc (ADIL) Stock Price, Quote & News

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen...

Industry: Biotechnology

Sector: Healthcare

Phone: 804 487 8196

Website: www.adial.com

Address:

4870 Sadler Road, Suite 300, Glen Allen, United States

StayPresent May. 12 at 7:33 PM

$ADIL after the next RS and subsequent dilution, they should probably have enough money to conduct a ph3 trial.

0 · Reply

Patrik605 May. 12 at 5:46 PM

$ADIL 💤 😴 💤 💤 💤

0 · Reply

Mikemelga2024 May. 11 at 5:55 PM

$ADIL 🤷‍♂️🤷‍♂️🤷‍♂️

1 · Reply

uptrend2025 May. 7 at 9:13 PM

$ADIL Will bring heavy artillery mañana and push this back up where it belongs 👀

1 · Reply

StayPresent May. 7 at 8:43 PM

$ADIL five pennies

0 · Reply

Patrik605 May. 7 at 8:43 PM

$ADIL Just replace this demented management and the price will skyrocket higher than with all the news they've released in the last year. Maybe they themselves need medication and maybe even a change of job because they haven't done anything. They lied and disappointed many investors.

0 · Reply

uptrend2025 May. 7 at 6:53 PM

$ADIL What changed? Negative posts won’t help you if you are still in this. Sell and move on if you haven’t.

2 · Reply

uptrend2025 May. 7 at 4:56 PM

$ADIL Nice dip. Waiting on news. 👀

0 · Reply

Patrik605 May. 7 at 4:13 PM

$ADIL Total incompetent **holes. They've been on the hook for a year and their solution is dilution again?

0 · Reply

Patrik605 May. 7 at 2:02 PM

$ADIL I'd be interested in their workday... Incompetent amateurs.

0 · Reply

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

2026-04-29T16:56:08.000Z - 13 days ago

Adial Pharmaceuticals files AD04 utility application with USPTO

Apr 29, 2026, 9:07 AM EDT - 14 days ago

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

2026-04-27T13:29:38.000Z - 16 days ago

Adial submits AD04 product application for FDA CNPV pilot program

Apr 27, 2026, 8:47 AM EDT - 16 days ago

Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

2026-04-22T13:57:56.000Z - 21 days ago

Adial Pharmaceuticals completes AD04 demonstration batch production

Apr 22, 2026, 9:35 AM EDT - 21 days ago

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

2026-03-06T13:06:13.000Z - 2 months ago

Adial Pharmaceuticals expects cash to fund operations into 2H of 2026

2026-03-03T13:35:20.000Z - 2 months ago

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

2026-02-24T14:07:23.000Z - 2 months ago

Adial Pharmaceuticals regains compliance with Nasdaq listing requirement

Feb 24, 2026, 9:00 AM EST - 2 months ago

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

2026-02-23T13:48:10.000Z - 2 months ago

Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden

Feb 23, 2026, 8:30 AM EST - 2 months ago

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

2026-02-11T13:46:03.000Z - 3 months ago

Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim

2026-02-06T00:50:11.000Z - 3 months ago

Adial Pharmaceuticals trading halted, news pending

2026-02-05T14:38:47.000Z - 3 months ago

Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?

Feb 4, 2026, 9:35 AM EST - 3 months ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

2026-02-03T22:05:26.000Z - 3 months ago

Adial Pharmaceuticals announces 1-for-25 reverse stock split

Feb 3, 2026, 4:05 PM EST - 3 months ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

2026-01-14T14:05:52.000Z - 4 months ago

Adial announces publication of international patent application for AD04

2025-11-26T13:05:42.000Z - 6 months ago

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

2025-11-14T13:35:16.000Z - 6 months ago

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Oct 17, 2025, 9:00 AM EDT - 7 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

2025-10-09T12:40:33.000Z - 7 months ago

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

Oct 9, 2025, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

2025-09-30T11:40:10.000Z - 8 months ago

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

2025-09-16T12:16:04.000Z - 8 months ago

Adial announces receipt of final meeting minuts from EOP2 meeting with FDA

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

2025-09-03T12:41:40.000Z - 9 months ago

Adial granted a 180 calendar day extension by Nasdaq to regain compliance

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Jul 16, 2025, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

May 15, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 2, 2025, 11:48 AM EDT - 1 year ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 1, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Mar 4, 2025, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Feb 25, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 19, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 12, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Jan 29, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

May 29, 2024, 8:30 AM EDT - 2 years ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 15, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Mar 1, 2024, 7:00 PM EST - 2 years ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Feb 28, 2024, 9:30 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

StayPresent May. 12 at 7:33 PM

$ADIL after the next RS and subsequent dilution, they should probably have enough money to conduct a ph3 trial.

0 · Reply

Patrik605 May. 12 at 5:46 PM

$ADIL 💤 😴 💤 💤 💤

0 · Reply

Mikemelga2024 May. 11 at 5:55 PM

$ADIL 🤷‍♂️🤷‍♂️🤷‍♂️

1 · Reply

uptrend2025 May. 7 at 9:13 PM

$ADIL Will bring heavy artillery mañana and push this back up where it belongs 👀

1 · Reply

StayPresent May. 7 at 8:43 PM

$ADIL five pennies

0 · Reply

Patrik605 May. 7 at 8:43 PM

0 · Reply

uptrend2025 May. 7 at 6:53 PM

$ADIL What changed? Negative posts won’t help you if you are still in this. Sell and move on if you haven’t.

2 · Reply

uptrend2025 May. 7 at 4:56 PM

$ADIL Nice dip. Waiting on news. 👀

0 · Reply

Patrik605 May. 7 at 4:13 PM

$ADIL Total incompetent **holes. They've been on the hook for a year and their solution is dilution again?

0 · Reply

Patrik605 May. 7 at 2:02 PM

$ADIL I'd be interested in their workday... Incompetent amateurs.

0 · Reply

Patrik605 May. 6 at 8:57 PM

$ADIL The whole thing stinks of selfishness and their manipulation. They said something they must have known they were incapable of (start phase 3 in the end of 2025). That's why they gave the shares to employees for free only now and not six months ago. After the price fell by 90 percent. Incompetent management. And they want new investors? When they behave like this?

0 · Reply

Patrik605 May. 6 at 8:42 PM

$ADIL They are selfish and they wipe their asses with investors and lie to them, even though they must know in advance that they are not capable of it (I am talking about starting phase 3 at the end of 2025). They probably had a year's vacation after completing phase 2... At their pace, someone more capable will come with a new drug, go through 2 phases and find capable investors before Adial is even able to start phase 3.. They have not resolved anything at all.. No partnership, nothing. They wanted to start phase 3 at the end of 2025.. In 2026, at the end of April, they will announce that they already have drugs ready for phase 3... Really Bravo, bravo, bravo. Replace these incompetent people.

0 · Reply

Patrik605 May. 6 at 8:32 PM

$ADIL No wonder... They slept for 3/4 of the year. They brought absolutely nothing. Especially since they wanted to start phase 3 at the end of 2025. They are lying liars. This should be punishable. When after 3/4 of a year they gave away free shares themselves, they started publishing reports and doing something that they already had before the end of 2025 and it would have moved the price a lot.

0 · Reply

Perfect_Thinking May. 6 at 7:51 PM

$ADIL is this still alive? I was thinking its done.. even with news neither its moves not it falls..strange

0 · Reply

uptrend2025 May. 6 at 2:40 PM

$ADIL you need to have lots of patience with this one

0 · Reply

Patrik605 May. 6 at 1:28 PM

$ADIL Their pace is killer. So the main thing is that "we will start phase 3 by the end of 2025". Liars.

0 · Reply

kshonstocks May. 4 at 5:55 PM

$ADIL hitting the off the bottom scans, keep an eye

0 · Reply

Patrik605 May. 1 at 2:09 PM

$ADIL Sleeping Beauty. This management is totally tragic and their progress is at a snail's pace. They want investors, but they lie to them and act disgustingly and selfishly. That's why this stock is bottoming out every day. No stock falls like this mess and management is responsible for it.

0 · Reply

StayPresent May. 1 at 10:55 AM

$ADIL some more fluff news from the Adial Idiots and we should set the All Time Low today

1 · Reply

OfficialStocktwitsUser Apr. 30 at 7:26 PM

$ADIL RSI: 45.95, MACD: -0.1160 Vol: 0.05, MA20: 1.60, MA50: 1.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Patrik605 Apr. 30 at 1:50 PM

$ADIL Even stocks where only one promising candidate recently failed are much more popular than this! The management of this company has completely screwed up. They have been doing absolutely nothing for a year. They have not brought us any results from their work for almost a whole year, but they wanted to start the phase at the end of 2025 - they lied to us! Now they have given away free shares to their employees and suddenly woke up with applications that they could have submitted much earlier. They only care about their own pockets. But it is no wonder that now it has no positive effect on the price (too bad for them). It is disgusting! Replace this management.

0 · Reply

Patrik605 Apr. 30 at 9:04 AM

$ADIL Amateurs, with their own approach and incompetent management, totally screwed up the potential and value of this stock.

0 · Reply

Market Cap	2.06M
Revenue (ttm)	0.00
Net Income (ttm)	-7.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	43,900
Avg Vol	127,016
Day's Range	N/A - N/A
Shares Out	1.43M
Stochastic %K	9%
Beta	1.27
Analysts	Strong Sell
Price Target	$25.00